Therefore, we propose that TIM-3 has a critical role in immunosuppression and it should be targeted as a novel therapeutic mechanism in the treatment of digestive tumours such as pancreatic cancer. This evidence concerns the gene HAVCR2 and familial pancreatic carcinoma.